Jiri Minarik

Olomouc, Czech Republic

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 93 publications

BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal Function.

BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal Function.

Journal: Clinical lymphoma, myeloma & leukemia
Published: February 16, 2026

Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

Journal: Blood cancer discovery
Published: December 03, 2025

Regulatory function of ten‑eleven translocation‑2 in transcriptional mechanisms of demethylated myeloma cells.

Regulatory function of ten‑eleven translocation‑2 in transcriptional mechanisms of demethylated myeloma cells.

Journal: Molecular medicine reports
Published: December 02, 2025

Autologous stem cell transplantation for newly diagnosed multiple myeloma - real-world data from 2,149 Czech patients.

Autologous stem cell transplantation for newly diagnosed multiple myeloma - real-world data from 2,149 Czech patients.

Journal: Haematologica
Published: November 13, 2025

Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.

Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 08, 2025

Multi-hit TP53 confers the poorest survival in multiple myeloma in the era of novel therapies.

Multi-hit TP53 confers the poorest survival in multiple myeloma in the era of novel therapies.

Journal: Molecular medicine (Cambridge, Mass.)
Published: July 29, 2025

Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.

Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.

Journal: Blood cancer journal
Published: July 08, 2025

Multiplatform comparisons and annotation of structural variants highlight the utility of the T2T reference genome in human diagnostics.

Multiplatform comparisons and annotation of structural variants highlight the utility of the T2T reference genome in human diagnostics.

Journal: GigaScience
Published: June 26, 2025

Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies.

Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies.

Journal: Clinical lymphoma, myeloma & leukemia
Published: June 10, 2025

Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.

Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 03, 2025

De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysis.

De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysis.

Journal: Annals of hematology
Published: May 28, 2025

Final Results of a Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma.

Final Results of a Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma.

Journal: EJHaem
Published: April 15, 2025
Showing 1-12 of 93

Last Updated: 09/26/2026